IRX4204
Issued US Patents for Cancers
- The company owns issued US patents for use of IRX4204 for treatment of diverse cancers including lung, breast, prostate, and pancreatic.
- The company owns issued US patents for treatment of HER2+ breast cancer with IRX4204 in combination with multiple other agents with which it has demonstrated synergistic therapeutic effects, including anti-HER2 monoclonal antibodies, HER2 tyrosine kinase inhibitors, and taxanes.
- The company has issued and pending patents for use of IRX4204 for treatment of HER2 cancers resistant to HER2 monoclonal antibodies or HER2 tyrosine kinase inhibitors.
Issued US Patents for Neurodegenerative Diseases
- Monotherapy treatment with IRX4204 of any neurologic condition, either central or peripheral, which involves both neuroinflammation and demyelination.
- Combination treatments of IRX4204 with thyroid hormone, and optionally, neurotrophic factors, for aging related neurodegeneration, AD, PD, MS, ALS, Stroke, brain or spinal cord trauma, hypoxic brain injury, schizophrenia, depression, and autism.
Issued US Patents for Autoimmune Diseases
- Autoimmune inflammatory arthritis (RA, OA, PSA, AS, Juvenile arthritis); psoriasis, eczema, and other autoimmune skin diseases; Crohn’s disease, ulcerative colitis, and celiac disease; and asthma and other allergic diseases.
Issued International Patents for Neurodegenerative and Autoimmune Diseases
- The company owns issued patents for Parkinson’s disease; as well as for many of the above listed neurodegenerative and autoimmune indications in Europe, Japan, South Korea, China, Hong Kong, Singapore, Australia, New Zealand, Canada, Mexico, Israel, and South Africa.
The company owns issued and pending patents for methods of synthesis of IRX4204, and for analogues of IRX4204.
The company owns issued and pending US and international patents for compositions and formulations with improved delivery .
IRX5183
The company owns issued patents in the U.S. and Europe for use of IRX5183 for treatment of multiple myeloma.